

## A Health and Wellness Company


Columbia Care is one of the largest multi-state operators in the medical cannabis industry, with licenses across 15 jurisdictions in the U.S. and the EU. Columbia Care's patient-centric approach has its foundation in the data it collects from each patient interaction which it then leverages to create a differentiated portfolio of pharmaceutical-quality products and deliver exceptional patient experiences.

The "Health and Wellness" segment in which Columbia Care competes is a large category that encompasses serious medical issues such as severe epilepsy and neuropathy, as well as acute issues such as anxiety, sleep, relaxation and general well-being. Through its wide range of products – from precise, unit-dosed, controlled hard-pressed tablets, tinctures and suppositories to high-purity CBD products that can be purchased with or without a medical cannabis card – Columbia Care seeks to address some of the world's most challenging unmet medical needs.

For more information on Columbia Care, please visit <http://www.col-care.com>.

## Summary Financial Information

Ticker:	NEO:CCHW	<b>Revenue (as of Mar 31, 2019)</b>	
Price (C\$)*:	9.10	Q1 '19 (US\$):	12.9MM
Shares Outstanding:	216.1MM	Q1 '19 Growth:	45% y-o-y
Market Cap (C\$)*:	2.0BN	TTM (US\$):	43.3MM
	<i>* as of market close May 9, 2019</i>	FY 2018 (US\$):	39.3MM



## Investment Highlights

### **Vertically-Integrated, One of the Largest Licensed U.S. Operator Footprints**

- 35 licenses in 15 jurisdictions across U.S. and E.U.; management estimates license portfolio permits access to ~ 50% of the U.S. adult population
- 54 facilities operational or in development with capital to expand footprint
- Diversified distribution: brick and mortar dispensaries, home delivery, wholesaling relationships and third-party licensing

### **Domestic Growth; International Expansion**

- Strong track record of organic growth since inception
- First quarter 2019 revenue growth of 45% from 2018
- Approved for cultivation, processing and distribution in the E.U. (Malta, Nov 2018)

### **Patient-Centric; Health & Wellness Focused**

- Pharmaceutical-quality formulation with precision dosing in a broad range of product categories with patents pending
- Established partnerships with leading research institutions for development of new products and applications to better serve patient needs
- Recent launch of new line of high-purity CBD products

### **Data-Driven; Branded Product Lines**

- Extensive cannabis patient database drives product innovation; provides basis for research collaboration with numerous global development partners
- Proprietary branded products with intellectual property

### **Management, Ownership and Governance**

- Management ownership of ~ 40% demonstrates clear alignment with shareholders
- Extensive knowledge of regulated and innovation-based industries

## Press Releases

May 08, 2019

[Columbia Care Launches "100,000,000 Ways to Break the Opioid Crisis" Initiative](#)

May 08, 2019


[Columbia Care Releases Preliminary Results for First Quarter 2019 and Full Year 2018](#)

Mar. 26, 2019

[Columbia Care Announces Peer-Reviewed Publication in Collaboration with New York University Detailing Medical Cannabis Use Among Cancer and Non-Cancer Patients in The Journal of Palliative Medicine](#)


### Strong Track Record of Organic Growth

(\$US 000's)



### Cultivation and Manufacturing Footprint

(excludes Columbia Care's multiple industrial hemp permits)



#### Research Partnerships

Ongoing collaborations with top academic and research institutions, including:

- Columbia University
- New York University
- The Center for Discovery
- University of Pittsburgh
- Stanford University

#### Management Team

**Nicholas Vita**  
Chief Executive Officer  
**Michael Abbott**  
Executive Chairman  
**David Hart**  
Chief Operating Officer  
**Lars Boesgaard**  
Chief Financial Officer  
**Bryant Ison**  
Chief Marketing Officer

**Dr. Rosemary Mazanet**  
Chief Scientific Officer  
**Bryan Olson**  
Chief Human Capital Officer  
**Guy Hussussian**  
Chief Data Officer  
**Mary-Alice Miller**  
Chief Risk Officer & General Counsel

#### Board of Directors

**Igor Gimalshtein**  
Zola Global Investors  
**John Howard**  
Irving Place Capital  
**James A.C. Kennedy**  
Former CEO, T Rowe Price  
**Jonathan P. May**  
Floresta Partners  
**David F. Solomon**  
Hildred Capital Partners

### Broad Portfolio of Pharmaceutical-Quality Products Address the Needs of Consumers and Patients



### Patient-Centric Dispensaries (Smyrna, DE; Brooklyn, NY)

